A Bluebird on My Shoulder…

The recent bluebird bio IPO has further buoyed expectations for gene therapy, early stage biotech and rare diseases. Is the euphoria justified? Perhaps for investors. But bluebird still has a ways to go before it has an approved therapy, as do other recent biotech IPO winners. So, what can we infer from the market’s Zip-A-Dee-Doo-Dah mindset – particularly in the face of so many concerns elsewhere? A couple of things, I think: They see rare diseases as a category likely to avoid being squeezed by downward pricing pressures from the Affordable Care Act and the broader burden of health costs in our economy. Thus, the potential payoff...

Here’s to the Next 25

Feinstein Kean Healthcare has spent the past 25 years laboring productively in the vineyards of disruptive innovation. The firm was born in the cradle of biotech and worked with many of the industry’s pioneers. We were there in the early days of stem cell research, oncogenes and immunotherapies, nanotech, many of the “omics” and, more recently, big data, cognitive gaming and the digitization of medicine. We’ve helped to open up entirely new categories of treatment in many disease areas, and changed the mindset in others. We were the first in the communications industry to anticipate the impact of personalized medicine—and (thanks...